Published date: 4 October 2023

Last edited date: 10 October 2023

Closed early engagement


Closing date: 16 October 2023

Contract summary

Industry

  • Health services - 85100000

Location of contract

LS2 7UE

Procurement reference

CF-1914500D0O000000rwimUAA

Published date

4 October 2023

Closing date

16 October 2023

Contract type

Service contract

Contract is suitable for SMEs?

Yes

Contract is suitable for VCSEs?

No

Description

You are invited to attend a virtual market engagement for the Cancer Vaccine Launch Pad (CVLP).

Overview
The CVLP is a strategic priority and collaboration between NHS England, the Department of Health and Social Care (DHSC), the Office for Life Sciences (OLS), the National Institute of Health Research (NIHR) and Genomics England (GEL), with the aim to facilitate access to personalised cancer vaccine research trials. The project was jointly announced in July 2023 with the Secretary of State and in partnership with the Prime Minister. See link (https://www.gov.uk/government/news/major-agreement-to-deliver-new-cancer-vaccine-trials#:~:text=It will work by creating,become part of standard care)

Through the CVLP platform, cancer patients from across a network of up to 140 NHS cancer care providers will be asked to consent to be put forward for clinical trials. Their surplus tissue samples, obtained through standard of care pathways, will be used to assess their eligibility. The detail of any available trials will be shared with the participant and their treating clinical team to see if the patient wishes to take part, and if so, the patient will travel to the nearest trial site to access the clinical trial.

The CVLP is company agnostic and is being set up in a phased approach with a small number of Trusts to test the pathway from September 2023. For the first phase, the CVLP is supporting one cancer vaccine clinical trial. It is likely that three to four additional trials will be brought into the CVLP during 2024.

NHS England is looking for a supplier to provide the digital infrastructure and clinical liaison function to manage the end-to-end pathway of the CVLP for up to 2000 patients until March 2025. The supplier will be expected to have strong clinical academic leadership and experience delivering large scale, multi-centre clinical trials in patients in the UK.

Estimated spend (excl. VAT): £1,400,000

Estimated Duration: 15 months

Contract duration:
Proposed contract start date: 01/01/2024
Proposed contract end date: 31/03/2025

Date of event: October 17th, 2023, 9.30am - 11:00am

Attendees are limited to 2 per company. To register your interest please contact england.cancervaccinelaunchpad@nhs.net and state the names and titles of those intending to attend.

Thank you.

More information

Previous notice about this procurement

Cancer Vaccine Launchpad (CVLP)

  • Early engagement
  • Published 4 October 2023

About the buyer

Contact name

NHSE Commercial Team

Address

Quarry Hill
Leeds
LS2 7UE
GB

Email

england.cancervaccinelaunchpad@nhs.net